Research programme: ion channel modulators - Lectus Therapeutics

Drug Profile

Research programme: ion channel modulators - Lectus Therapeutics

Alternative Names: Cav2.2 ion channel modulator - Lectus; voltage-gated potassium channel modulators - Lectus

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lectus Therapeutics
  • Class Small molecules
  • Mechanism of Action Ion channel modulators; N-type calcium channel modulators; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris; Multiple sclerosis; Neuropathic pain; Urinary incontinence

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom (PO)
  • 30 Sep 2010 No development reported for Multiple sclerosis in United Kingdom (unspecified route)
  • 28 Feb 2009 No development reported - Preclinical for Angina pectoris in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top